A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Diagnosed with type 2 diabetes for at least 6 months

• Blood glucose criteria must be met

• BMI in the range 22-40

Exclusion Criteria:

• History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes

• Use of thiazolidinediones or need for insulin within 3 months prior to screening

• Significant concomitant diseases or complications of diabetes

• High fasting triglycerides as defined by the protocol

Other protocol-defined inclusion/exclusion criteria may apply